The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Issue 6 (November 2016)

• Record Type: Journal Article
• Authors: Barbui, T.; Thiele, J.; Gisslinger, H.; Finazzi, G.; Vannucchi, A.M.; Tefferi, A.
• Is Part Of: Blood reviews. Volume 30:Issue 6(2016:Nov.)
• Page Start: 453
• Page End: 459
• Publication Date: 2016-11
• Subjects: Polycythemia vera -- Essential thrombocythemia -- Prefibrotiy/early primary myelofibrosis -- Overt primary myelofibrosis -- Revision -- Clinical aspects; Hematology -- Periodicals; Hematology -- Periodicals; Hématologie -- Périodiques; Hematology; Electronic journals; Periodicals; 616.15
• DOI: 10.1016/j.blre.2016.06.001
• Languages: English
• ISSNs: 0268-960X

Abstract

Abstract: Clinical evidence supports the need of changing the diagnostic criteria of the 2008 updated WHO classification for polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). In JAK2 -mutated patients who show characteristic bone marrow (BM) morphology, clinical studies demonstrated that a hemoglobin level of 16.5 g/dL in men and 16.0 g/dl for women or a hematocrit value of 49% in men and 48% in women are the optimal cut off levels for distinguishing JAK2 -mutated ET from "masked/prodromal" PV. Therefore BM morphology was upgraded to a major diagnostic criterion. Regarding ET the key issue was to improve standardization of prominent BM features enhancing differentiation between "true" ET and prefibrotic/early primary myelofibrosis (prePMF). These two entities have shown a different epidemiology and clinical outcomes. Concerning prePMF a more explicit clinical characterization of minor criteria is mandated for an improved distinction from ET and overt PMF and accurate diagnosis and outcome prediction.